 h. lundbeck a/s (commonly known simply as lundbeck) is a danish international pharmaceutical company engaged in the research and development, production, marketing, and sale of drugs for the treatment of disorders in the central nervous system (cns), including depression, schizophrenia, alzheimer's disease, parkinson's disease, huntington's disease, epilepsy and insomnia.lundbeck.com headquartered in copenhagen, denmark lundbeck has international production facilities in denmark, mexico, italy and france and affiliates or sales offices in 57 countries. lundbeck employs around 5.500 people globally (as of 2013), and the companyâs products are registered in more than 100 countries world wide. in 2013, the company's revenue was dkk 15.2 billion (â¬2.04 billion). lundbeck is listed on the copenhagen stock exchange (cse). lundbeck is a full member of the european federation of pharmaceutical industries and associations (efpia) and of the international federation of pharmaceutical manufacturers and associations (ifpma) ==history== the company was founded by hans lundbeck in 1915, and was initially a trading company supplying a variety of goods to the danish market, including machinery for manufacturing, aluminium foil, artificial sweeteners, and photographic equipment. lundbeck entered the pharmaceutical market in 1924, importing medicines and cosmetics from companies based in other european and american countries. by the late 1930s, lundbeck had begun to produce its own medicinal products and had established its own research department. production continued during the second world war, although it was limited due to a lack of raw materials. after the war, lundbeck continued to grow and in 1957 the company introduced truxal (chlorprothixene) for the treatment of schizophrenia, entering the market for brain disorders. in 1954, the lundbeck foundation was established to maintain and e
Companies_based_in_Copenhagen Life_science_companies_based_in_Copenhagen Pharmaceutical_companies_of_Denmark Valby